Scientists: Novel TB drug combo passes first test

July 23, 2012 by LAURAN NEERGAARD

Scientists are hot on the trail of a new tuberculosis treatment that a small study suggests might one day offer an alternative to battle this deadly lung disease, even if it is resistant to today's two main drugs.

There have not been new medications to treat TB in four decades. But the experimental three-, revealed Monday at the International AIDS Conference, is one of a list of promising compounds under intense testing around the world.

"We are cautiously optimistic that we are at the dawn of a new era for ," Dr. Diane Havlir of the University of California, San Francisco, who is co-chairing the meeting, told The Associated Press. She wasn't involved with the new research.

TB is one of the world's oldest killers, and every year it claims the lives of more than 1.5 million people, mostly in developing countries. It's also the leading killer of people with AIDS.

Standard first-line treatment requires taking four medications for six months. A frightening factor is that the bacteria that cause TB are fast becoming impervious to the two main drugs in that cocktail. The estimates there are more than 650,000 cases of multidrug-resistant TB a year. Treating -resistant TB can take more than two years, if it works at all.

Enter the new drug research.

Scientists in South Africa divided 85 newly diagnosed to take a variety of combinations of standard or experimental TB drugs,

Fifteen of the patients received a unique trio that emerged as the study's focus: An experimental antibiotic code-named PA-824, along with the pneumonia drug moxifloxacin and an older TB drug, .

In a two-week test, the drug trio killed at least as much of the that patients coughed up as today's standard four-drug therapy, and possibly worked a bit faster, said Dr. Mel Spigelam of the nonprofit TB Alliance, the Global Alliance for TB Drug Development.

That does not mean patients were cured in two weeks, stressed lead researcher Dr. Andreas Diacon of South Africa's Stellenbosch University. It takes longer to get the last TB bugs lurking deep in the lungs — the reason that TB therapy must be taken for months — but a two-week test is a standard first step in drug development.

It is noteworthy that the experimental combination doesn't include either of the two standard TB drugs — isoniazid and rifampicin — that today cause most problems of drug resistance. If additional research proves the drug trio really works, it could offer a much-needed alternative for multidrug-resistant TB as well, Spigelman said. Plus, it might be helpful for HIV patients who have trouble with today's TB treatments interacting badly with their anti-AIDS medicines.

A larger study has begun in South Africa, Tanzania and Brazil that will test how patients fare over two months. Monday's study, funded by the Bill and Melinda Gates Foundation and other groups, also was reported in the journal Lancet.

As important, the study showed a new way to research TB treatments that scientists hope will cut years off the lengthy process, said Mario Raviglione of the World Health Organization. Today, possible new drugs are tested simply by adding them onto standard treatment rather the TB Alliance approach of testing novel combinations from the beginning.

A few other promising TB drugs are further along in the pipeline. Johnson & Johnson recently filed for U.S. approval of its bedaquiline, which it hopes will become the first medicine specifically designated to treat multidrug-resistant TB. In a late-stage study this autumn, the company will test whether it can shorten therapy time for those especially hard-to-treat . And Otsuka Pharmaceutical Co. is studying its own drug, named delamanid.

Explore further: Trial for new drug-resistant TB treatment to begin

shares

Related Stories

Trial for new drug-resistant TB treatment to begin

March 19, 2012
A global health alliance Monday unveiled plans for the first clinical tests of a new treatment regimen for tuberculosis, including for patients with resistance to existing multidrug programs.

Trial signals major milestone in hunt for new TB drugs

July 23, 2012
A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two ...

Recommended for you

Groundbreaking investigative effort identifies gonorrhea vaccine candidates

September 19, 2017
Researchers at Oregon State University have identified a pair of proteins that show promise as the basis for a gonorrhea vaccine.

Snail fever progression linked to nitric oxide production

September 14, 2017
Bilharzia, caused by a parasitic worm found in freshwater called Schistosoma, infects around 200 million people globally and its advance can lead to death, especially in children in developing countries.

Systems analysis points to links between Toxoplasma infection and common brain diseases

September 13, 2017
More than 2 billion people - nearly one out of every three humans on earth, including about 60 million people in the United States - have a lifelong infection with the brain-dwelling parasite Toxoplasma gondii.

Study clears important hurdle toward developing an HIV vaccine

September 13, 2017
An international team of researchers has demonstrated a way of overcoming one of the major stumbling blocks that has prevented the development of a vaccine against HIV: the ability to generate immune cells that stay in circulation ...

As 'flesh-eating' Leishmania come closer, a vaccine against them does, too

September 13, 2017
Parasites that ulcerate the skin, can disfigure the face, and may fatally mutilate its victim's internal organs are creeping closer to the southern edges of the United States.

Promising clinical trial results could give doctors a new tool against drug-resistant strains of malaria parasite

September 13, 2017
Tulane University researchers have developed a new drug that is effective against non-severe cases of malaria, according to results from an FDA-supervised clinical trial published in the latest issue of The Lancet Infectious ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.